authoritative systematic reviews and meta-analyses are quoted below.
x Acupuncture for chronic pain (including rheumatological conditions): "Various sources of bias ... precluded a conclusive finding". 12 x Homoeopathy for all indications (including rheumatoid arthritis and other rheumatological conditions): "the clinical eVects of homoeopathy are (not) completely due to placebo ...," 13 implying that homoeopathy has, on average, clinical eVects beyond the placebo eVect.
x Chiropractic for back pain: there is "no convincing evidence for the eVectiveness of chiropractic for acute or chronic low back pain." 14 Such reviews can be criticised, not least because of the heterogeneity of the original trials included. Systematic reviews on defined rheumatological conditions would therefore be more helpful. Unfortunately, the evidence emerging from work of this nature is even less compelling. A recent review of acupuncture as a treatment of inflammatory rheumatic diseases, for instance, concluded that this form of therapy "cannot be recommended." 15 My own review related to osteoarthritis found that "the most rigorous studies suggest that acupuncture is not superior to sham-needling." 16 This most sobering state of aVairs is diYcult to reconcile with the success of CM in everyday clinical practice. Most of those who use CM are satisfied with it and many try CM because of disappointment with mainstream medicine. 17 18 As argued above, the reasons for perceived eVectiveness may often lie in the quality and character of care more than the specifics of the given therapy. A recent survey, for instance, implied that arthritis suVerers who use CM and mainstream medicine in parallel, consistently rate the quality of the therapeutic relationship with CM practitioners higher than that with conventional doctors. 19 If a given (complementary or orthodox) treatment were devoid of specific eVects, this would not necessarily mean that it is totally useless. There may be a case for evidencebased placebo treatments. Non-specific eVects can be an important part of the total therapeutic eVect of any treatment, mainstream or complementary. 7 This area is much neglected by present research. We need to understand the "ins and outs" of non-specific eVects better than we do at present. 20 This type of inquiry is by no means aimed at denigrating CM but at determining how best to Annals of the Rheumatic Diseases optimise non-specific eVects and at finding out how they can be used more widely to the benefit of the patient. There may be important lessons to learn, also for mainstream rheumatology.
One essential precondition would, however, be safety. CM is often promoted and perceived to be entirely safe. Yet, practitioners should know better. Quite simply, there will never be a therapy that is totally free of risk. In conventional medicine, risks are routinely recognised, monitored, and quantified. This is essential for balancing them against the benefit of a given treatment. Only if the potential benefits outweigh the potential risks will we use this therapy. What sounds like a platitude to physicians, amounts to a veritable revolution for complementary practitioners. In CM, comparable risk benefit analyses are rarely possible: not only are we uncertain about the benefits of most complementary therapies (see above), we also know far too little about the risks of CM. All we do know is that complications, even serious ones, are on record, 21 but we cannot even begin to estimate their frequency. In addition to the issue of "direct" adverse eVects, there is a further, neglected "indirect" safety issue: even if a given complementary therapy were entirely safe, the complementary therapists might not be. An example might be the over use of radiography by chiropractors. 22 Most experts agree that the best way ahead lies in conducting rigorous research. We all know that the randomised controlled trial is not a flawless research tool. But for establishing therapeutic eYcacy there is, generally speaking, no better method for excluding bias. What applies to mainstream medicine also applies to CM; there can be no room for double standards. 23 Future research eVorts might be structured in the following way. Systematic reviews and meta-analyses should establish what is presently known and define specific research questions. In turn, these should be investigated with the most rigorous research design possible. It is true that in CM some trials cannot be conducted in a double blind and placebo controlled fashion. Yet, randomised controlled trials are practically always possible and desirable. 23 Areas of priority might lie in testing the eYcacy of acupuncture and plant-based remedies for defined rheumatological conditions. Whenever possible, investigations into the biological, psychological and cultural mechanisms of action of CM should be conducted in parallel. Such research would establish how given treatments work once it is clear (or at least likely) that they work. As there is far less commercial interest in CM than in conventional (drug) therapy, the money for such research would need to come, to a large extent, from public funds.
The bottom line of all this seems clear. "Evidence-based CM" must no longer remain a contradiction in terms. We need to be able to advise our patients responsibly about the risks and benefits of these treatments. 24 Failing to take this challenge would be nothing less than disregarding the best interests of our patients. 
